Company intelligence / Profile preview

Vast Therapeutics

Chapel Hill, North Carolina, United Statesvasttherapeutics.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Vast Therapeutics has developed a proprietary platform of nitric oxide-releasing small molecules with dual anti-inflammatory and antimicrobial mechanisms. Their lead programs are in preclinical or lead optimization stages targeting chronic respiratory diseases such as cystic fibrosis, non-CF bronchiectasis, COPD, and nontuberculous mycobacterial infections. The company’s technology aims to address both the infectious and inflammatory components of these conditions using inhaled formulations. No published human clinical results yet.

Therapeutic areas: PulmonologyInfectious Diseases
Modalities: Small molecules (specifically nitric oxide-releasing compounds/prodrugs)
Industry: Biotech

Drug pipeline

3 assets

ALX1

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Vast Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vast Therapeutics.

Explore the full profile